Oncurious translates VIB research into potential new cancer treatments

Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Research carried out by Peter Carmeliet (VIB-KU Leuven) and colleagues provided the basis for a new potential drug: TB-403. Their research showed that TB-403 has the potential to greatly improve the treatment of edulloblastoma and a number of other pediatric tumors, an area of great medical need. In parallel, the VIB-KU Leuven labs of Massimiliano Mazzone and Gabriele Bergers, and the VIB-VUB lab of Jo Van Ginderachter discovered new targets in the immuno-oncology space.

Based on the positive results, VIB and Oxurion set up the joint venture Oncurious in 2015, to accelerate the development of TB-403 for the treatment of pediatric tumors. In 2017, Oncurious acquired a portfolio of nextgeneration immuno-oncology assets from VIB, propelling the company into the area of immunooncology.

The VIB Discovery Sciences team takes the lead in the pre-clinical development of the company’s pipeline of cancer immunotherapies, steered by the scientific input of the VIB founding labs.

Oncurious is currently testing the TB-403 therapy in patients. A Phase I/IIa program evaluating TB-403 in medulloblastoma patients is ongoing. The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. On top of that, Oncurious is developing the pipeline of five next-generation immuno-oncology compounds targeting a broad spectrum of cancers.